BioCentury | May 26, 2020
Distillery Therapeutics

Disrupting mitochondrial DNA-mediated paracrine signaling for prostate cancer

DISEASE CATEGORY: Cancer INDICATION: Prostate cancer Targeting a cancer-associated fibroblast signaling pathway triggered by mitochondrial DNA (mtDNA) released from prostate cancer cells could treat prostate cancer and enhance the efficacy of docetaxel in resistant tumors....
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | Apr 11, 2020
Emerging Company Profile

Clover: trimerizing fusion proteins

Clover is developing trimerized fusion proteins to target cancer and infectious disease pathways that depend on trimer formation. The company has exclusive, worldwide rights to its Trimer-Tag platform from GenHunter Corp., which was co-founded by...
BioCentury | Mar 27, 2020
Product Development

COVID-19 roundup: biopharmas scramble to reassess clinical timelines; plus CEPI-Dynavax, and emergency approvals for Vero, Fosun

More than a dozen biopharmas Thursday announced delays or disruptions to clinical programs and regulatory timelines as companies begin to turn their attention to managing their trials through the COVID-19 crisis. The setbacks came as...
BioCentury | Feb 8, 2020
Product Development

Coronavirus biology: where products in clinical testing intervene

The 13 therapies in clinical trials to treat coronavirus map to at least half a dozen mechanisms, intervening at three different steps in the viral cycle or manipulating different aspects of the host immune response....
BC Extra | Nov 14, 2019
Company News

Via Allergan hair loss deal, Exicure builds balance sheet to advance oncology, neurology pipeline

A collaboration deal giving Allergan options to obtain rights to Exicure's hair loss programs will provide the biotech with non-dilutive cash to further advance a pipeline of spherical nucleic acid (SNA) therapeutics for oncology, neurology...
BC Extra | Aug 28, 2019
Clinical News

Aug. 28 Clinical Quick Takes: InDex's cobitolimod hits Phase IIb endpoint in UC; plus AstraZeneca and Mitsubishi

InDex's UC therapy heading for Phase III  InDex Pharmaceuticals Holding AB (SSE:INDEX) is planning Phase III testing of cobitolimod after the DNA-based immunomodulatory sequence (DIMS) therapy met the primary endpoint in the Phase IIb CONDUCT...
BioCentury | Jun 10, 2019
Finance

$80M series B backs Oncologie's biomarkers, which could give new life to old therapies

Oncologie's strategy of pairing in-licensed, later-stage compounds with biomarkers led Nan Fung Life Sciences and Pivotal bioVenture Partners China to return to invest in the cancer company's tranched $80 million series B. The funds are...
BC Week In Review | Mar 22, 2019
Financial News

Dynavax commercializing Heplisav-B with $75M debt financing

To fund the commercialization of its Heplisav-B HBV vaccine, Dynavax announced March 18 it was drawing down a $75 million non-dilutive loan through an existing agreement with CRG Servicing LLC. Dynavax Technologies Corp. (NASDAQ:DVAX) drew...
BC Innovations | Mar 14, 2019
Translation in Brief

Bacteriophages: double-edged swords

Utah researchers have shown bacteriophage-host immune interactions can trigger adverse immune responses in GI diseases, a factor phage companies may need to take into account. Phage researchers have long thought mammalian host immunity recognizes the...
Items per page:
1 - 10 of 530